1504 GMT - GSK's 3Q performance was mixed, with a profit beat but weakened vaccines sales, Barclays analysts say in a note. The British pharma giant delivered expectations at the group level but missed sales estimates for its key vaccine shots that led the company to lower its annual vaccine segment outlook, they say. Investors' focus will be on the sales outlook for the next two years for its RSV vaccine Arexvy and its best-selling shingles vaccine Shingrix, Barclays says. Shares fall 3.6% to 14 pounds. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
October 30, 2024 11:04 ET (15:04 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Comments